

Talazoparib for treating HER2-negative advanced breast cancer with germline BRCA mutations

Information for the public

Published: 21 February 2024

www.nice.org.uk

Talazoparib is available on the NHS as a possible treatment for HER2-negative, locally advanced or metastatic breast cancer with inherited (germline) BRCA1 or BRCA2 mutations in adults who have had:

- an anthracycline or a taxane, or both, unless these treatments are not suitable, and
- endocrine therapy if they have hormone receptor (HR)-positive breast cancer, unless this is not suitable.

If you are not eligible for talazoparib but are already having it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. See [our webpage on making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS webpage on breast cancer in women](#) or [breast cancer in men](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Breast Cancer Now](#), 0800 800 6000
- [METUPUK](#), join-us@metupuk.org.uk
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-5725-5